"Using double-blinded in vivo experiments, we then applied the wound-healing peptide UN3 with a peptide created during a previous study, named comb1. We found that, together, the 2 outperformed all control groups, including the only FDA-approved growth factor-containing drug for treating diabetic wounds, becaplermin," said first author, Tatiana Demidova-Rice, PhD. UN3 was created and modified from 2 naturally occurring peptides that are normally present in trace amounts and found in human platelet-rich plasma. "The confirmation that these peptides could act synergistically to improve human wound healing moves our research one significant step closer to clinical application….Clinical trials using the peptides will be the next step," said Ira Herman, PhD, professor of molecular physiology and pharmacology at Tufts University School of Medicine.
(Source: ScienceDaily, February 24, 2012)F